Skin cells and red blood cells of affected people will have low levels of β-glucuronidase activity. Sly syndrome can also be diagnosed through prenatal testing. Treatment
Vestronidase alfa-vjbk (trade name Mepsevii), an enzyme replacement therapy which is a recombinant form of human β-glucuronidase, is approved by U.S. Food and Drug Administration for the treatment of Sly syndrome. Hematopoietic stem cell transplant (HSCT) has been used to treat other types of MPS diseases, but this is not yet available for MPS-VII. Animal experiments suggest that HSCT may be an effective treatment for MPS-VII in humans. Prognosis
The life expectancy of individuals with MPS VII varies depending on the symptoms. Some individuals are stillborn, while some may survive into adulthood. Epidemiology
MPS-VII is one of the rarest forms of MPS. It occurs in less than 1 in 250,000 births. As a family, MPS diseases occur in 1 in 25,000 births, and the larger family of lysosomal storage diseases occur in 1 out of 7,000 to 8,000 births. History
Sly syndrome was originally discovered in 1972. It was named after its discoverer William S. Sly, an American biochemist who has spent nearly his entire academic career at Saint Louis University. References


== External links ==
In circumstances where a person is showing possible signs of aphasia, the physician will refer him or her to a speech-language pathologist (SLP) for a comprehensive speech and language evaluation. SLPs will examine the individuals ability to express him or herself through speech, understand language in written and spoken forms, write independently, and perform socially.The American Speech, Language, Hearing Association (ASHA) states a comprehensive assessment should be conducted in order to analyze the patients communication functioning on multiple levels; as well as the effect of possible communication deficits on activities of daily living. Typical components of an aphasia assessment include: case history, self report, oral-motor examination, language skills, identification of environmental and personal factors, and the assessment results. A comprehensive aphasia assessment includes both formal and informal measures.Formal assessments include:

Boston Diagnostic Aphasia Examination (BDAE): diagnoses the presence and type of aphasia, focusing on location of lesion and the underlying linguistic processes. Western Aphasia Battery – Revised (WAB): determines the presence, severity, and type of aphasia; and can also determine baseline abilities of patient. Communication Activities of Daily Living - Second Edition (CADL-2): measures functional communication abilities; focuses on reading, writing, social interactions, and varying levels of communication. Revised Token Test (RTT): assess receptive language and auditory comprehension; focuses on patients ability to follow directions.Informal assessments, which aid in the diagnosis of patients with suspected aphasia, include:
Conversational speech and language sample
Family interview
Case history or medical chart review
Behavioral observationsDiagnostic information should be scored and analyzed appropriately.